We are live on !
Find out more
Hampstead Capital Portfolio holdings
AUM
$55.8M
Turnover
0%
1-Year Est. Return
2.76%
This Fund
S&P 500
This Quarter Est. Return
+5.29%
1 Year Est. Return
+2.76%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$55.8M
AUM Growth
+$2.64M
(+5%)
Cap. Flow
+$33.7K
Cap. Flow % of AUM
Cap. Flow %
0.06%
Top 10 Holdings %
Top 10 Hldgs %
72.24%
Holding
24
New
–
Increased
4
Reduced
6
Closed
–
Avg Time Held
1.5
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Southern Company
SO
|
+$465K |
| 2 |
Chevron
CVX
|
+$218K |
| 3 |
Philip Morris
PM
|
+$164K |
| 4 |
PPL Corp
PPL
|
+$164K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$564K |
| 2 |
Verizon
VZ
|
+$127K |
| 3 |
Royal Bank of Canada
RY
|
+$110K |
| 4 |
AT&T
T
|
+$84.3K |
| 5 |
ExxonMobil
XOM
|
+$65.4K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 19.95% |
| 2 | Energy | 19.86% |
| 3 | Utilities | 15.89% |
| 4 | Consumer Staples | 15.38% |
| 5 | Healthcare | 14.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
AT&T
T
$146B
| $4.82M | 8.64% |
190,126
-3,443
| -2% | -$84.3K |
2016 Q4
7 quarters
|
|
|
2
Philip Morris
PM
$308B
| $4M | 7.15% |
49,000
+2,000
| +4% | +$164K |
2016 Q4
7 quarters
|
|
|
3
PPL Corp
PPL
$26.9B
| $3.99M | 7.15% |
136,400
+5,600
| +4% | +$164K |
2016 Q4
7 quarters
|
|
|
4
Southern Company
SO
$108B
| $3.99M | 7.14% |
91,500
+10,100
| +12% | +$465K |
2016 Q4
7 quarters
|
|
5
Coca-Cola
KO
$412B
| $3.97M | 7.11% |
86,000
-600
| -0.7% | -$27.4K |
2017 Q2
5 quarters
|
|
|
6
Verizon
VZ
$189B
| $3.94M | 7.05% |
73,700
-2,400
| -3% | -$127K |
2016 Q4
7 quarters
|
|
|
7
Pfizer
PFE
$168B
| $3.93M | 7.04% |
94,017
-14,650
| -13% | -$564K |
2016 Q4
7 quarters
|
|
|
8
Chevron
CVX
$415B
| $3.91M | 7.01% |
32,000
+1,800
| +6% | +$218K |
2017 Q2
5 quarters
|
|
|
9
Royal Bank of Canada
RY
$278B
| $3.9M | 6.99% |
48,700
-1,400
| -3% | -$110K |
2016 Q4
7 quarters
|
|
|
10
ExxonMobil
XOM
$677B
| $3.88M | 6.96% |
45,700
-800
| -2% | -$65.4K |
2016 Q4
7 quarters
|
|
11
T-Mobile US
TMUS
$172B
| $2.39M | 4.27% |
34,000
| – | – |
2016 Q4
7 quarters
|
|
12
Gilead Sciences
GILD
$207B
| $1.58M | 2.83% |
20,500
| – | – |
2016 Q4
7 quarters
|
|
13
Innovex International
INVX
$1.76B
| $1.49M | 2.67% |
28,500
| – | – |
2017 Q3
4 quarters
|
|
14
Fluor
FLR
$6.22B
| $1.36M | 2.44% |
23,500
| – | – |
2017 Q2
5 quarters
|
|
15
American International
AIG
$40.3B
| $1.14M | 2.05% |
21,500
| – | – |
2016 Q4
7 quarters
|
|
16
Expro Ltd
XPRO
$1.47B
| $1.02M | 1.83% |
19,583
| – | – |
2016 Q4
7 quarters
|
|
17
Merck
MRK
$362B
| $993K | 1.78% |
14,672
| – | – |
2017 Q3
4 quarters
|
|
|
CELG
18
DELISTED
Celgene Corp
CELG
| $984K | 1.76% |
11,000
| – | – |
2016 Q4
7 quarters
|
|
19
DELISTED
Trinseo
TSE
| $940K | 1.68% |
12,000
| – | – |
2017 Q4
3 quarters
|
|
20
Exelon
EXC
$47.2B
| $895K | 1.6% |
28,741
| – | – |
2017 Q2
5 quarters
|
|
21
Viatris
VTRS
$22.8B
| $824K | 1.48% |
22,500
| – | – |
2016 Q4
7 quarters
|
|
22
DELISTED
Pioneer Natural Resource Co.
PXD
| $784K | 1.4% |
4,500
| – | – |
2016 Q4
7 quarters
|
|
23
Procter & Gamble
PG
$383B
| $624K | 1.12% |
7,500
| – | – |
2018 Q1
2 quarters
|
|
24
General Motors
GM
$73.1B
| $471K | 0.84% |
14,000
| – | – |
2016 Q4
7 quarters
|
|
Similar funds
CCP
PAI
SF
BOIA
Hampstead Capital's Q3 2018 Portfolio in Review
As of Q3 2018, Hampstead Capital held 24 positions worth $55.8M, up 5% from $53.2M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Trading was light in Q3 2018: portfolio turnover was 0%. Hampstead Capital opened no new positions and made no exits, leaving the 24-position portfolio largely intact.
By sector, the portfolio is most concentrated in Communication Services at 20% of assets, up from 20% a quarter earlier, followed by Energy and Utilities.
- Hampstead Capital added most to Southern Company in Q3 2018, an estimated $465K increase.
- Hampstead Capital's biggest Q3 2018 reduction was Pfizer, cutting an estimated $564K.
- Hampstead Capital's ten largest holdings make up 72% of its $55.8M portfolio in Q3 2018.
- Hampstead Capital opened 0 new positions and closed 0 in Q3 2018.
- Hampstead Capital's portfolio value rose 5% quarter-over-quarter to $55.8M.
Based on Hampstead Capital's 13F filing for Q3 2018, filed 14 Nov 2018.